Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Periodicals
Acutus shares would be worth $28 at Atricure's valuation, Kerrisdale says » 09:26
07/21/21
07/21
09:26
07/21/21
09:26
AFIB

Acutus Medical

$13.42 /

+0.03 (+0.22%)

, ATRC

AtriCure

$79.54 /

+2.35 (+3.04%)

, BSX

Boston Scientific

$42.80 /

+1.595 (+3.87%)

, MDT

Medtronic

$125.52 /

+2.75 (+2.24%)

Kerrisdale Capital…

Kerrisdale Capital published a report outlining its long thesis on Acutus Medical (AFIB), in which the firm stated in part: "Despite operating in a multi-billion dollar market growing at high double digit rates, Acutus trades at about 8x the next twelve months' consensus revenue estimates, and at just 5x our 2022 estimate of $76M in revenues, a valuation on par with mega-cap medical device companies like Boston Scientific (BSX) and Medtronic (MDT), and a steep discount to more rapidly growing upstarts. Atricure (ATRC), the only other public company exclusively dedicated to ablation devices, trades at more than 11x consensus estimates for its 2022 revenues despite the fact that its surgical ablation end markets are growing much more slowly than the catheter ablation market, and its core products are existentially threatened by catheter ablation advances. At Atricure's valuation, Acutus shares would be worth $28, more than double their current price, and still offer the prospect of multiplying several times over as AcQMap becomes the standard of care in complex arrhythmias." In pre-market trading, Acutus shares have risen $1.25, or 9%, to $14.69. Reference Link

ShowHide Related Items >><<
MDT Medtronic
$125.52 /

+2.75 (+2.24%)

BSX Boston Scientific
$42.80 /

+1.595 (+3.87%)

ATRC AtriCure
$79.54 /

+2.35 (+3.04%)

AFIB Acutus Medical
$13.42 /

+0.03 (+0.22%)

AFIB Acutus Medical
$13.42 /

+0.03 (+0.22%)

07/15/21 Canaccord
Acutus Medical upgraded to Buy on signs of commercial traction at Canaccord
07/15/21 Canaccord
Acutus Medical upgraded to Buy from Hold at Canaccord
03/19/21 Canaccord
Acutus Medical price target lowered to $16 from $30 at Canaccord
03/19/21 William Blair
Acutus Medical downgraded to Market Perform from Outperform at William Blair
ATRC AtriCure
$79.54 /

+2.35 (+3.04%)

06/15/21 Stifel
AtriCure price target raised to $85 from $72 at Stifel
05/26/21 SVB Leerink
AtriCure price target raised to $95 from $78 at SVB Leerink
05/14/21 JPMorgan
AtriCure price target raised to $81 from $70 at JPMorgan
04/30/21 Canaccord
AtriCure price target raised to $102 from $77 at Canaccord
BSX Boston Scientific
$42.80 /

+1.595 (+3.87%)

06/07/21 Argus
Boston Scientific price target raised to $50 from $45 at Argus
05/26/21
Fly Intel: Top five analyst downgrades
05/26/21 Needham
Boston Scientific downgraded to Hold at Needham on overextended consensus
05/26/21 Needham
Boston Scientific downgraded to Hold from Buy at Needham
MDT Medtronic
$125.52 /

+2.75 (+2.24%)

07/21/21 Evercore ISI
Intuitive Surgical price target raised to $980 from $825 at Evercore ISI
06/10/21 Truist
Aziyo Biologics price target lowered to $16 from $20 at Truist
06/07/21 Piper Sandler
Piper cuts Aziyo target but sees Medtronic sticking with company
06/03/21 Piper Sandler
Piper stays Overweight Medtronic after HeartWare HVAD device discontinued
MDT Medtronic
$125.52 /

+2.75 (+2.24%)

BSX Boston Scientific
$42.80 /

+1.595 (+3.87%)

ATRC AtriCure
$79.54 /

+2.35 (+3.04%)

AFIB Acutus Medical
$13.42 /

+0.03 (+0.22%)

  • 15
    Jul
  • 06
    Aug
AFIB Acutus Medical
$13.42 /

+0.03 (+0.22%)

BSX Boston Scientific
$42.80 /

+1.595 (+3.87%)

AFIB Acutus Medical
$13.42 /

+0.03 (+0.22%)

MDT Medtronic
$125.52 /

+2.75 (+2.24%)

BSX Boston Scientific
$42.80 /

+1.595 (+3.87%)

AFIB Acutus Medical
$13.42 /

+0.03 (+0.22%)

Over a month ago
Conference/Events
AtriCure management to meet virtually with Oppenheimer » 04:55
06/22/21
06/22
04:55
06/22/21
04:55
ATRC

AtriCure

$76.46 /

+1.91 (+2.56%)

Virtual Meeting to be…

Virtual Meeting to be held on June 22 hosted by Oppenheimer.

ShowHide Related Items >><<
ATRC AtriCure
$76.46 /

+1.91 (+2.56%)

ATRC AtriCure
$76.46 /

+1.91 (+2.56%)

06/15/21 Stifel
AtriCure price target raised to $85 from $72 at Stifel
05/26/21 SVB Leerink
AtriCure price target raised to $95 from $78 at SVB Leerink
05/14/21 JPMorgan
AtriCure price target raised to $81 from $70 at JPMorgan
04/30/21 Canaccord
AtriCure price target raised to $102 from $77 at Canaccord
ATRC AtriCure
$76.46 /

+1.91 (+2.56%)

Conference/Events
AtriCure management to meet virtually with Oppenheimer » 09:49
06/21/21
06/21
09:49
06/21/21
09:49
ATRC

AtriCure

$74.59 /

+0.04 (+0.05%)

Virtual Meeting to be…

Virtual Meeting to be held on June 22 hosted by Oppenheimer.

ShowHide Related Items >><<
ATRC AtriCure
$74.59 /

+0.04 (+0.05%)

ATRC AtriCure
$74.59 /

+0.04 (+0.05%)

06/15/21 Stifel
AtriCure price target raised to $85 from $72 at Stifel
05/26/21 SVB Leerink
AtriCure price target raised to $95 from $78 at SVB Leerink
05/14/21 JPMorgan
AtriCure price target raised to $81 from $70 at JPMorgan
04/30/21 Canaccord
AtriCure price target raised to $102 from $77 at Canaccord
ATRC AtriCure
$74.59 /

+0.04 (+0.05%)

Conference/Events
AtriCure management to meet virtually with Oppenheimer » 04:55
06/18/21
06/18
04:55
06/18/21
04:55
ATRC

AtriCure

$77.40 /

+1.44 (+1.90%)

Virtual Meeting to be…

Virtual Meeting to be held on June 18 hosted by Oppenheimer.

ShowHide Related Items >><<
ATRC AtriCure
$77.40 /

+1.44 (+1.90%)

ATRC AtriCure
$77.40 /

+1.44 (+1.90%)

06/15/21 Stifel
AtriCure price target raised to $85 from $72 at Stifel
05/26/21 SVB Leerink
AtriCure price target raised to $95 from $78 at SVB Leerink
05/14/21 JPMorgan
AtriCure price target raised to $81 from $70 at JPMorgan
04/30/21 Canaccord
AtriCure price target raised to $102 from $77 at Canaccord
ATRC AtriCure
$77.40 /

+1.44 (+1.90%)

Conference/Events
AtriCure management to meet virtually with Oppenheimer » 14:03
06/16/21
06/16
14:03
06/16/21
14:03
ATRC

AtriCure

$76.41 /

-1.47 (-1.89%)

Virtual Meeting to be…

Virtual Meeting to be held on June 18 hosted by Oppenheimer.

ShowHide Related Items >><<
ATRC AtriCure
$76.41 /

-1.47 (-1.89%)

ATRC AtriCure
$76.41 /

-1.47 (-1.89%)

06/15/21 Stifel
AtriCure price target raised to $85 from $72 at Stifel
05/26/21 SVB Leerink
AtriCure price target raised to $95 from $78 at SVB Leerink
05/14/21 JPMorgan
AtriCure price target raised to $81 from $70 at JPMorgan
04/30/21 Canaccord
AtriCure price target raised to $102 from $77 at Canaccord
ATRC AtriCure
$76.41 /

-1.47 (-1.89%)

Recommendations
AtriCure price target raised to $85 from $72 at Stifel » 06:49
06/15/21
06/15
06:49
06/15/21
06:49
ATRC

AtriCure

$76.78 /

+0.78 (+1.03%)

Stifel analyst Rick Wise…

Stifel analyst Rick Wise raised the firm's price target on AtriCure to $85 from $72 and keeps a Buy rating on the shares. Wise is "highly optimistic" after speaking with a key study author/investigator of last week's LAAOS-III New England Journal of Medicine publication about the potential positive implications for Atricure's left atrial appendage exclusion device AtriClip, which represents about 40% of sales, the analyst tells investors in a research note. At a minimum, Wise views the study findings and the physician's feedback as solidly-supporting sustained 20%+ AtriClip/AtriCure total sales growth outlook.

ShowHide Related Items >><<
ATRC AtriCure
$76.78 /

+0.78 (+1.03%)

ATRC AtriCure
$76.78 /

+0.78 (+1.03%)

05/26/21 SVB Leerink
AtriCure price target raised to $95 from $78 at SVB Leerink
05/14/21 JPMorgan
AtriCure price target raised to $81 from $70 at JPMorgan
04/30/21 Canaccord
AtriCure price target raised to $102 from $77 at Canaccord
04/29/21 Piper Sandler
AtriCure price target raised to $85 from $70 at Piper Sandler
ATRC AtriCure
$76.78 /

+0.78 (+1.03%)

Recommendations
AtriCure price target raised to $95 from $78 at SVB Leerink » 08:57
05/26/21
05/26
08:57
05/26/21
08:57
ATRC

AtriCure

$71.60 /

-0.83 (-1.15%)

SVB Leerink analyst…

SVB Leerink analyst Danielle Antalffy raised the firm's price target on AtriCure to $95 from $78 and keeps an Outperform rating on the shares after hosting management meetings. The analyst notes that "not surprisingly," CONVERGE was a key focus of the investor group meeting we held with CONVERGE potentially expanding the company's TAM by almost 2.5 times. But management also highlighted the strength of the base business, noting expectations for AtriCure's open ablation and clip businesses together to continue to drive sales growth in the low-to-mid teens range for the foreseeable future, Antalffy adds. Overall, Antalffy remains one of the analyst's top SMID-Cap picks for 2021 as she views the company as a TAM expansion story, with CONVERGE opening up the market opportunity to the 3.6M of atrial fibrillation patients that are longstanding persistent who have limited effective therapy options available to them today.

ShowHide Related Items >><<
ATRC AtriCure
$71.60 /

-0.83 (-1.15%)

ATRC AtriCure
$71.60 /

-0.83 (-1.15%)

05/14/21 JPMorgan
AtriCure price target raised to $81 from $70 at JPMorgan
04/30/21 Canaccord
AtriCure price target raised to $102 from $77 at Canaccord
04/29/21 Piper Sandler
AtriCure price target raised to $85 from $70 at Piper Sandler
04/28/21 Oppenheimer
AtriCure price target raised to $75 from $65 at Oppenheimer
ATRC AtriCure
$71.60 /

-0.83 (-1.15%)

Conference/Events
AtriCure management to meet virtually with Piper Sandler » 08:17
05/25/21
05/25
08:17
05/25/21
08:17
ATRC

AtriCure

$72.22 /

+0.11 (+0.15%)

Virtual Meeting to be…

Virtual Meeting to be held on May 25 hosted by Piper Sandler.

ShowHide Related Items >><<
ATRC AtriCure
$72.22 /

+0.11 (+0.15%)

ATRC AtriCure
$72.22 /

+0.11 (+0.15%)

05/14/21 JPMorgan
AtriCure price target raised to $81 from $70 at JPMorgan
04/30/21 Canaccord
AtriCure price target raised to $102 from $77 at Canaccord
04/29/21 Piper Sandler
AtriCure price target raised to $85 from $70 at Piper Sandler
04/28/21 Oppenheimer
AtriCure price target raised to $75 from $65 at Oppenheimer
ATRC AtriCure
$72.22 /

+0.11 (+0.15%)

Recommendations
AtriCure price target raised to $81 from $70 at JPMorgan » 07:45
05/14/21
05/14
07:45
05/14/21
07:45
ATRC

AtriCure

$70.46 /

-0.21 (-0.30%)

JPMorgan analyst Robbie…

JPMorgan analyst Robbie Marcus raised the firm's price target on AtriCure to $81 from $70 and keeps an Overweight rating on the shares. With Convergent approval in hand, AtriCure is at a "notable turning point in the business as it begins rolling out its MIS procedures in earnest," Marcus tells investors in a research note. The analyst says that with no other on-label solutions or competitive trials in the works, the path is clear for AtriCure to capture the $250M long-standing persistent market. He sees there's room for "significant upside beyond these levels" as the company drives referrals and potentially captures the patients who failed previous catheter ablations.

ShowHide Related Items >><<
ATRC AtriCure
$70.46 /

-0.21 (-0.30%)

ATRC AtriCure
$70.46 /

-0.21 (-0.30%)

04/30/21 Canaccord
AtriCure price target raised to $102 from $77 at Canaccord
04/29/21 Piper Sandler
AtriCure price target raised to $85 from $70 at Piper Sandler
04/28/21 Oppenheimer
AtriCure price target raised to $75 from $65 at Oppenheimer
04/28/21 BTIG
AtriCure price target raised to $76 from $69 at BTIG
ATRC AtriCure
$70.46 /

-0.21 (-0.30%)

Recommendations
AtriCure price target raised to $102 from $77 at Canaccord » 07:44
04/30/21
04/30
07:44
04/30/21
07:44
ATRC

AtriCure

$76.00 /

+6.07 (+8.68%)

Canaccord analyst William…

Canaccord analyst William Plovanic raised the firm's price target on AtriCure to $102 from $77 and keeps a Buy rating on the shares. The analyst cited the company's announcement of the FDA PMA approval of the EPi-Sense System for treatment of patients diagnosed with long standing persistent AF; the first and only approval of its kind.

ShowHide Related Items >><<
ATRC AtriCure
$76.00 /

+6.07 (+8.68%)

ATRC AtriCure
$76.00 /

+6.07 (+8.68%)

04/29/21 Piper Sandler
AtriCure price target raised to $85 from $70 at Piper Sandler
04/28/21 Oppenheimer
AtriCure price target raised to $75 from $65 at Oppenheimer
04/28/21 BTIG
AtriCure price target raised to $76 from $69 at BTIG
04/12/21 Canaccord
AtriCure price target raised to $77 from $69 at Canaccord
ATRC AtriCure
$76.00 /

+6.07 (+8.68%)

  • 12
    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.